Exploiting Conformational Dynamics in Drug Discovery: Design of C-Terminal Inhibitors of Hsp90 with Improved Activities
暂无分享,去创建一个
Giorgio Colombo | Elisabetta Moroni | Huiping Zhao | Brian S. J. Blagg | G. Colombo | E. Moroni | B. Blagg | Huiping Zhao
[1] B. Blagg,et al. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. , 2008, Current medicinal chemistry.
[2] H. Nymeyer,et al. Simulation of the folding equilibrium of α-helical peptides: A comparison of the generalized Born approximation with explicit solvent , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Mok,et al. Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90 , 2006, Journal of Biological Chemistry.
[4] L. Pearl,et al. Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex , 2006, Nature.
[5] R. Rappuoli,et al. The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. , 2007, Drug discovery today.
[6] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[7] Carsten Kutzner,et al. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.
[8] David A. Agard,et al. Structural Analysis of E. coli hsp90 Reveals Dramatic Nucleotide-Dependent Conformational Rearrangements , 2006, Cell.
[9] Johannes Buchner,et al. Hsp90 is regulated by a switch point in the C‐terminal domain , 2009, EMBO reports.
[10] B. Blagg,et al. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. , 2008, The Journal of organic chemistry.
[11] R. Nussinov,et al. The origin of allosteric functional modulation: multiple pre-existing pathways. , 2009, Structure.
[12] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[13] Beat Ernst,et al. Drug discovery today. , 2003, Current topics in medicinal chemistry.
[14] J. Zorn,et al. Turning enzymes ON with small molecules. , 2010, Nature chemical biology.
[15] Ruben Abagyan,et al. ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..
[16] P. Kollman,et al. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .
[17] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[18] Lila M Gierasch,et al. The changing landscape of protein allostery. , 2006, Current opinion in structural biology.
[19] Anshuman Dixit,et al. Elucidation of the Hsp90 C-terminal inhibitor binding site. , 2011, ACS chemical biology.
[20] C. Chennubhotla,et al. Coupling between global dynamics and signal transduction pathways: a mechanism of allostery for chaperonin GroEL. , 2008, Molecular bioSystems.
[21] R. Nussinov,et al. Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms , 2009, Molecular bioSystems.
[22] J. Mccammon,et al. Molecular recognition and ligand association. , 2013, Annual review of physical chemistry.
[23] J Andrew McCammon,et al. Studying functional dynamics in bio-molecules using accelerated molecular dynamics. , 2011, Physical chemistry chemical physics : PCCP.
[24] J A McCammon,et al. Accommodating protein flexibility in computational drug design. , 2000, Molecular pharmacology.
[25] Heather A. Carlson,et al. Incorporating Dynamics in E. coli Dihydrofolate Reductase Enhances Structure-Based Drug Discovery , 2007, J. Chem. Inf. Model..
[26] F. Bushman,et al. Developing a dynamic pharmacophore model for HIV-1 integrase. , 2000, Journal of medicinal chemistry.
[27] Elisabetta Moroni,et al. 3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. , 2013, ACS medicinal chemistry letters.
[28] Adam Godzik,et al. Divergent evolution of protein conformational dynamics in dihydrofolate reductase , 2013, Nature Structural &Molecular Biology.
[29] David A Agard,et al. Conformational dynamics of the molecular chaperone Hsp90 , 2011, Quarterly Reviews of Biophysics.
[30] Gennady Verkhivker,et al. Dynamics-Based Discovery of Allosteric Inhibitors: Selection of New Ligands for the C-terminal Domain of Hsp90. , 2010, Journal of chemical theory and computation.
[31] J Andrew McCammon,et al. Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple docking approach. , 2002, Journal of the American Chemical Society.
[32] X. Daura,et al. Peptide Folding: When Simulation Meets Experiment , 1999 .
[33] J. Peyrat,et al. Recent advances in Hsp90 inhibitors as antitumor agents. , 2008, Anti-cancer agents in medicinal chemistry.
[34] Paul Workman,et al. Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.
[35] Stewart A. Adcock,et al. Molecular dynamics: survey of methods for simulating the activity of proteins. , 2006, Chemical reviews.
[36] J. Wells,et al. Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.
[37] Giorgio Colombo,et al. Corresponding Functional Dynamics across the Hsp90 Chaperone Family: Insights from a Multiscale Analysis of MD Simulations , 2012, PLoS Comput. Biol..
[38] Ruben Abagyan,et al. A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE) , 2008, J. Comput. Aided Mol. Des..
[39] Andrew E. Torda,et al. The GROMOS biomolecular simulation program package , 1999 .
[40] Giorgio Colombo,et al. Modeling Signal Propagation Mechanisms and Ligand-Based Conformational Dynamics of the Hsp90 Molecular Chaperone Full-Length Dimer , 2009, PLoS Comput. Biol..
[41] Friedrich Förster,et al. Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90. , 2008, Structure.
[42] J Andrew McCammon,et al. Molecular docking of balanol to dynamics snapshots of protein kinase A , 2005, Proteins.
[43] Katrina W Lexa,et al. Protein flexibility in docking and surface mapping , 2012, Quarterly Reviews of Biophysics.
[44] Paul Workman,et al. Overview: translating Hsp90 biology into Hsp90 drugs. , 2003, Current cancer drug targets.
[45] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[46] Heather A. Carlson,et al. Automated clustering of probe molecules from solvent mapping of protein surfaces: new algorithms applied to hot-spot mapping and structure-based drug design , 2008, J. Comput. Aided Mol. Des..
[47] L. Neckers,et al. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. , 2000, Journal of the National Cancer Institute.
[48] Jason E Gestwicki,et al. Harnessing Chaperones to Generate Small-Molecule Inhibitors of Amyloid ß Aggregation , 2004, Science.
[49] G. Giaccone,et al. Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.
[50] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[51] Martin Hessling,et al. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis , 2009, Nature Structural &Molecular Biology.
[52] L. Neckers,et al. The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.
[53] Anthony Maxwell,et al. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. , 2006, Journal of the American Chemical Society.
[54] P. Sexton,et al. Molecular Pharmacology , 1965, Nature.
[55] Lila M. Gierasch,et al. Sending Signals Dynamically , 2009, Science.
[56] T. Straatsma,et al. THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .
[57] B. Blagg,et al. Targeting the heat shock protein 90 dimer with dimeric inhibitors. , 2011, Journal of medicinal chemistry.
[58] R. Nussinov,et al. The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.
[59] J Andrew McCammon,et al. On the use of molecular dynamics receptor conformations for virtual screening. , 2012, Methods in molecular biology.
[60] David A Agard,et al. Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. , 2008, Molecular cell.
[61] Heather A Carlson,et al. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. , 2007, Journal of the American Chemical Society.
[62] Berk Hess,et al. LINCS: A linear constraint solver for molecular simulations , 1997 .
[63] B. Blagg,et al. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. , 2011, Journal of medicinal chemistry.
[64] Heather A Carlson,et al. Differences between high- and low-affinity complexes of enzymes and nonenzymes. , 2008, Journal of medicinal chemistry.
[65] Johannes Buchner,et al. hsp90: Twist and Fold , 2006, Cell.
[66] Huiping Zhao,et al. Cytotoxic sugar analogues of an optimized novobiocin scaffold , 2010 .
[67] R. Immormino,et al. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. , 2007, Molecular cell.
[68] Xiao Ming Yu,et al. Hsp90 inhibitors identified from a library of novobiocin analogues. , 2005, Journal of the American Chemical Society.
[69] Claudio N. Cavasotto,et al. Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.